Laboratorio de Hepatología Experimental, Departamento de Farmacología, Cinvestav-IPN, Apartado Postal 14-740, Ciudad de México, Mexico.
Laboratorio de Enfermedades Hepáticas, Instituto Nacional de Medicina Genómica - INMEGEN, Ciudad de México, Mexico; Dirección de Cátedras, Consejo Nacional de Ciencia y Tecnología - CONACYT, Ciudad de México, Mexico.
Biochem Pharmacol. 2022 Jan;195:114845. doi: 10.1016/j.bcp.2021.114845. Epub 2021 Nov 18.
Hepatocellular carcinoma (HCC), the most common primary liver cancer, arises after a long period of exposure to etiological factors. Nonalcoholic steatohepatitis (NASH) is ranked as the main risk factor for developing HCC; hence, experimental models of NASH leading to HCC have become key tools both to investigate the molecular mechanisms underlying the pathophysiology and to evaluate new putative drugs for treating chronic liver diseases in humans. Animal models of NASH induced by a high-fat diet (HFD) plus chemical inducers, such as the NASH-HCC (STAM), high-fat diet/diethylnitrosamine (HFD/DEN), choline-deficient high-fat diet/DEN (CDHFD/DEN), and Western diet/carbon tetrachloride (WD/CCl) models, are promising because they exacerbate liver damage and significantly shorten the experimental time. In this review, we critically summarize and discuss the ability of these models to recapitulate the liver alterations that precede and lead to HCC progression, as well as the impact of the diet in promoting liver injury progression. We also emphasize the strengths and weaknesses of the models' ability to closely mimic the stages of liver injury development that occur in humans. Based on the molecular mechanisms induced by the currently available NASH models leading to HCC, we argue that although several NASH models have importantly contributed to describing the disease chronology, the progress in emulating the progression from NASH to HCC has been partial. Thus, the development of novel NASH/HCC models remains an unmet need.
肝细胞癌(HCC)是最常见的原发性肝癌,它是在长期暴露于病因因素后发生的。非酒精性脂肪性肝炎(NASH)被列为发展为 HCC 的主要危险因素;因此,导致 HCC 的 NASH 实验模型已成为研究发病机制分子机制以及评估治疗人类慢性肝病的新候选药物的关键工具。高脂肪饮食(HFD)加化学诱导剂(如 NASH-HCC [STAM]、高脂肪饮食/二乙基亚硝胺(HFD/DEN)、胆碱缺乏高脂肪饮食/二乙基亚硝胺(CDHFD/DEN)和西方饮食/四氯化碳(WD/CCl)模型)诱导的 NASH 动物模型很有前途,因为它们会加重肝损伤并显著缩短实验时间。在这篇综述中,我们批判性地总结和讨论了这些模型重现导致 HCC 进展之前和之后的肝脏改变的能力,以及饮食在促进肝损伤进展方面的影响。我们还强调了这些模型模拟人类肝损伤发展阶段的能力的优缺点。基于目前可用的 NASH 模型诱导 HCC 的分子机制,我们认为,尽管几种 NASH 模型对描述疾病的时间进程做出了重要贡献,但在模拟从 NASH 到 HCC 的进展方面,进展是部分的。因此,开发新的 NASH/HCC 模型仍然是一个未满足的需求。